Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Raoul Concepcion

Urology Nashville, TN Medical Doctor

NPI 1104801851 CMS profile 94985

28 White Bridge Rd, Suite 200, Nashville, TN 37205

Open in the dashboard

General payments

$338,765

353 records reported · program years 2019–2025

Research payments

$4,490

Paid to them · 4 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$6,734 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Raoul Concepcion of Nashville, TN is reported in the CMS Open Payments database as having received $338,765 across 353 general payments and $4,490 in research payments paid to them. Separately, studies naming them as principal investigator received $6,734 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $25,905 28
2024 General $30,757 32
2023 General $55,569 61
2022 General $66,423 77
2021 General $36,789 38
2021 Research $1,400 1
2020 General $40,268 34
2020 Research $3,090 3
2019 General $83,053 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Raoul Concepcion
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Raoul Concepcion were reported at $25,905. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Raoul Concepcion Urology median Middle half National median
2019 $83,053 $480 $147–$1,201 $163
2020 $40,268 $246 $87–$645 $114
2021 $36,789 $358 $111–$1,000 $132
2022 $66,423 $476 $143–$1,263 $149
2023 $55,569 $560 $168–$1,461 $160
2024 $30,757 $563 $170–$1,464 $164
2025 $25,905 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Astellas Pharma US Inc $133,949 97 payments
  2. Sun Pharmaceutical Industries Inc. $105,668 92 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $21,945 38 payments
  4. Ferring Pharmaceuticals Inc. $14,446 9 payments
  5. Clovis Oncology, Inc. $12,191 22 payments
  6. Dendreon Pharmaceuticals LLC $8,385 11 payments
  7. Janssen Scientific Affairs, LLC $7,560 13 payments
  8. Pfizer Inc. $6,311 7 payments
  9. Curium US LLC $6,122 6 payments
  10. Laborie Medical Technologies Corp. $4,800 1 payment
  11. Other $17,388 57 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $168,352 42 payments
  2. Consulting Fee $73,243 21 payments
  3. Travel and Lodging $48,047 126 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $21,313 5 payments
  5. Honoraria $12,715 6 payments
  6. Food and Beverage $12,095 152 payments
  7. Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program $3,000 1 payment
Products named General payments · program years 2019–2025
  1. XTANDI $108,856 80 payments
  2. YONSA $96,216 82 payments
  3. Nubeqa $15,438 28 payments
  4. Rubraca $12,191 22 payments
  5. FIRMAGON $8,613 3 payments
  6. PROVENGE $8,385 11 payments
  7. ERLEADA $8,147 21 payments
  8. Odomzo $7,783 6 payments
  9. Xofigo $6,414 9 payments
  10. Axumin $3,825 1 payment
  11. Other $21,820 50 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Pfizer Inc. $4,490 4 payments

Records

357 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record